Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dominant missense mutations in INF2 are linked to two diseases: focal segmental glomerulosclerosis, a kidney disease, and Charcot-Marie-Tooth disease, a neuropathy.
|
30962575 |
2019 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous mutations in the inverted formin-2 (INF2) gene provoke focal segmental glomerulosclerosis (FSGS) and intermediate Charcot-Marie-Tooth (CMT) disease with FSGS.
|
30680856 |
2019 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this case series, we present 3 adult patients who presented with advanced renal disease with the histological picture of FSGS and proved to have a genetic cause of the disease, namely, variants in INF2, COL4A4 and HNF1B, respectively.
|
31096240 |
2019 |
Focal glomerulosclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutational analysis of INF2 was performed on 109 patients (mean age at onset 41.44 ± 18.91 years) with FSGS or minimal change disease (MCD); and also in 6 patients without renal biopsy who had already developed chronic kidney disease (CKD)/ESRD at the time of diagnosis.
|
30126379 |
2018 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
INF2 mutations in patients with isolated FSGS are clustered in exons 2 to 4, encoding the diaphanous inhibitory domain, involved in the regulation of the podocyte actin cytoskeleton.
|
29038887 |
2018 |
Focal Segmental Glomerulosclerosis 5
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease.
|
27974406 |
2017 |
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease.
|
27974406 |
2017 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in inverted formin 2 (INF2), a member of the formin family of actin-regulating proteins, have recently been associated with a familial cause of nephrotic syndrome characterized by FSGS.
|
26764407 |
2016 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
INF2 mutations associated with dominant inherited intermediate Charcot-Marie-Tooth neuropathy with focal segmental glomerulosclerosis in two Chinese patients.
|
25943269 |
2016 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic analysis according to the Dutch guidelines of FSGS revealed a mutation in INF2.
|
26951353 |
2016 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
FSGS-causing INF2 mutations impair these interactions and disrupt the ability of INF2 to regulate Rho/Dia-mediated actin dynamics in vitro.
|
27350175 |
2016 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Novel mutations in the inverted formin 2 gene of Chinese families contribute to focal segmental glomerulosclerosis.
|
26039629 |
2015 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dominant INF2 mutations cause focal segmental glomerulosclerosis (FSGS), a kidney disease, and FSGS+Charcot-Marie-Tooth neuropathy.
|
25771894 |
2015 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recent advances show that human focal segmental glomerulosclerosis (FSGS) is a primary podocytopathy caused by podocyte-specific gene mutations including NPHS1, NPHS2, WT-1, LAMB2, CD2AP, TRPC6, ACTN4 and INF2.
|
26156092 |
2015 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
While earlier reports suggested that mutations causing FSGS-CMT are restricted to exons 2 and 3 of the INF2 gene, we found one CMT-FSGS causing mutation (p.Glu184Lys) in exon 4 extending the critical region of INF2 for rapid CMT-FSGS molecular genetic diagnosis.
|
25676889 |
2015 |
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Inverted formin 2-related Charcot-Marie-Tooth disease: extension of the mutational spectrum and pathological findings in Schwann cells and axons.
|
25676889 |
2015 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recently, mutations in the INF2 gene, which encodes inverted formin-2, were identified in patients with focal segmental glomerulosclerosis and a dominant intermediate form of CMT (CMTDIE, OMIM #614455).
|
24487800 |
2014 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We confirmed the high incidence of INF2 mutations in families with AD FSGS.
|
25165188 |
2014 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The INF2 mutation appears to be a major cause of CMT with FSGS.
|
24750328 |
2014 |
Focal glomerulosclerosis
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
We confirmed the high incidence of INF2 mutations in families with AD FSGS.
|
25165188 |
2014 |
Focal Segmental Glomerulosclerosis 5
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Novel INF2 mutations in an Italian cohort of patients with focal segmental glomerulosclerosis, renal failure and Charcot-Marie-Tooth neuropathy.
|
25165188 |
2014 |
Focal Segmental Glomerulosclerosis 5
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Novel INF2 mutations in an Italian cohort of patients with focal segmental glomerulosclerosis, renal failure and Charcot-Marie-Tooth neuropathy.
|
25165188 |
2014 |
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
A novel INF2 mutation in a Korean family with autosomal dominant intermediate Charcot-Marie-Tooth disease and focal segmental glomerulosclerosis.
|
24750328 |
2014 |
CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Novel INF2 mutations in an Italian cohort of patients with focal segmental glomerulosclerosis, renal failure and Charcot-Marie-Tooth neuropathy.
|
25165188 |
2014 |
Focal glomerulosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, this novel mutation in INF2 linked to nonsyndromic FSGS indicates the necessity for full gene sequencing if no mutation is found in the current rapid-screen region of the gene.
|
22971997 |
2013 |